Chabiotech (KOSDAQ:A085660) subsidiary Matica Biotechnology secured contract development and manufacturing organization (CDMO) contracts with Puerto Rico-based biotechnology company CytoImmune Therapeutics and Mongoose Bio for cell and gene therapies, Pulse News reported Wednesday.
Under the collaboration, Matica Bio will produce viral vectors at its dedicated good manufacturing practice (GMP) facility, while CytoImmune will handle cell therapy production at its Puerto Rico site for IND submission, Matica said last week.
Mongoose Bio will develop T-cell therapies for solid tumors with Matica's lentiviral vectors, the news report said.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: $17750.00, Change: $-80, Percent Change: -0.45%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。